SI0670162T1 - Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent - Google Patents

Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent

Info

Publication number
SI0670162T1
SI0670162T1 SI9530581T SI9530581T SI0670162T1 SI 0670162 T1 SI0670162 T1 SI 0670162T1 SI 9530581 T SI9530581 T SI 9530581T SI 9530581 T SI9530581 T SI 9530581T SI 0670162 T1 SI0670162 T1 SI 0670162T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulations
raloxifere
watersoluble
diluent
surfactant
Prior art date
Application number
SI9530581T
Other languages
English (en)
Slovenian (sl)
Inventor
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Stephanie Ann Sweetana
Arvind Lavji Thakkar
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0670162T1 publication Critical patent/SI0670162T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SI9530581T 1994-03-02 1995-02-28 Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent SI0670162T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
EP95301291A EP0670162B1 (en) 1994-03-02 1995-02-28 Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SI0670162T1 true SI0670162T1 (en) 2002-06-30

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530581T SI0670162T1 (en) 1994-03-02 1995-02-28 Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent

Country Status (22)

Country Link
EP (1) EP0670162B1 (zh)
JP (1) JP3574210B2 (zh)
CN (1) CN1098684C (zh)
AT (1) ATE211910T1 (zh)
AU (1) AU684882B2 (zh)
BR (1) BR9500758A (zh)
CA (1) CA2143263C (zh)
CZ (1) CZ286119B6 (zh)
DE (1) DE69524981T2 (zh)
DK (1) DK0670162T3 (zh)
ES (1) ES2166799T3 (zh)
FI (1) FI117042B (zh)
HU (1) HU225418B1 (zh)
IL (1) IL112746A (zh)
NO (1) NO314286B1 (zh)
NZ (1) NZ270588A (zh)
PL (1) PL178858B1 (zh)
PT (1) PT670162E (zh)
RU (1) RU2118540C1 (zh)
SG (1) SG65636A1 (zh)
SI (1) SI0670162T1 (zh)
ZA (1) ZA951497B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
CZ300341B6 (cs) * 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CA2219070C (en) * 1996-10-30 2007-12-18 Eli Lilly And Company Methods of preventing breast cancer
ZA979720B (en) 1996-10-30 1999-04-29 Lilly Co Eli Prophylaxis of breast cancer
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR100576149B1 (ko) * 1999-12-13 2006-05-03 추가이 세이야쿠 가부시키가이샤 하이드록시카보닐-할로게노알킬 측쇄를 갖는 화합물
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
MXPA03009683A (es) * 2001-04-24 2004-02-12 Merck Patent Gmbh TERAPIA EN COMBINACIoN USANDO AGENTES ANTIANGIOGENICOS Y FACTOR DE NECROSIS TUMORAL ALFA.
US7964734B2 (en) 2002-09-30 2011-06-21 A/S Gea Farmaceutisk Fabrik Raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2696984C (en) * 2007-10-16 2013-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
CL2008003799A1 (es) * 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
NZ620879A (en) 2009-04-24 2015-08-28 Iceutica Pty Ltd A novel formulation of indomethacin
WO2011000581A2 (en) * 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
DK2925320T3 (da) * 2012-11-30 2021-05-10 Pharmathen Sa Hidtil ukendt fremgangsmåde til forbedring af bio-tilgængeligheden af lægemidler med lav vandopløselighed
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2018062964A1 (ko) * 2016-09-30 2018-04-05 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
HU225418B1 (en) 2006-11-28
SG65636A1 (en) 1999-06-22
CZ49995A3 (en) 1995-10-18
NO314286B1 (no) 2003-03-03
FI950947A0 (fi) 1995-03-01
HUT72661A (en) 1996-05-28
NZ270588A (en) 1996-01-26
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
JPH07277973A (ja) 1995-10-24
BR9500758A (pt) 1995-10-24
JP3574210B2 (ja) 2004-10-06
RU2118540C1 (ru) 1998-09-10
IL112746A (en) 1999-12-31
DE69524981T2 (de) 2002-08-29
CA2143263A1 (en) 1995-09-03
ZA951497B (en) 1996-08-23
EP0670162A1 (en) 1995-09-06
FI117042B (fi) 2006-05-31
AU1354895A (en) 1995-09-07
CN1098684C (zh) 2003-01-15
HU9500635D0 (en) 1995-04-28
PL178858B1 (pl) 2000-06-30
CN1112420A (zh) 1995-11-29
ES2166799T3 (es) 2002-05-01
AU684882B2 (en) 1998-01-08
NO950799L (no) 1995-09-04
DK0670162T3 (da) 2002-03-11
PL307491A1 (en) 1995-09-04
CZ286119B6 (cs) 2000-01-12
IL112746A0 (en) 1995-05-26
FI950947A (fi) 1995-09-03
CA2143263C (en) 2002-01-08
ATE211910T1 (de) 2002-02-15
EP0670162B1 (en) 2002-01-16
DE69524981D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
SI0670162T1 (en) Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent
GB2341801B (en) Formulation
AU7221298A (en) Compounds
EP0948965A4 (en) STABLE MEDICAL COMPOSITIONS CONTAINING 4,5-EPOXYMORPHINE DERIVATIVES
EP0631789A3 (de) Vorrichtung zum Gasaustausch, insbesondere Oxygenierung in Blut.
EP0634459A3 (de) Formulierungen.
CA2163003A1 (en) Solubilizer and external preparations containing the same
EP0395287A3 (en) Dentifrice compositions
HUT71398A (en) Derivatives of dolastatin
AU4429885A (en) Solid medicament formulations containing dihydropyridines
AU8149291A (en) (2r)-2-{di(2-propyl)phosphonylmethoxy}-3-p- toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
TW270083B (zh)
AU2698992A (en) Freeflowing alkaline detergent, and agents for the preparation thereof
CA2216978A1 (en) Dentifrice formulations containing liquid polyoxyalkylene compounds miscible in a liquid, polyalkylene glycol carrier
AU3998497A (en) A combination preparation containing tramadol and a calcium channel antagonist
GR3022709T3 (en) Aerosol composition containing fusafungine.
MY117590A (en) Orally administerable pharmaceutical formulations
IT1258818B (it) Composizioni farmaceutiche orali a base di n5-metiltetraidrofolato di calcio
AU8086098A (en) Delta 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
IT234658Y1 (it) Corpo per cassetta postale.
AU8943398A (en) Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
IT228571Y1 (it) Involucro d'imballaggio,in particolare per feretri.